ImmunityBio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending June 30, 2025: 61.30%

ImmunityBio, Inc. Return on Equity (ROE) is 61.30% for the Trailing 12 Months (TTM) ending June 30, 2025, a -38.74% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • ImmunityBio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending June 30, 2024 was 100.06%, a 0.65% change year over year.
  • ImmunityBio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending June 30, 2023 was 99.42%, a -21.66% change year over year.
  • ImmunityBio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending June 30, 2022 was 126.90%.
Key Data
Date Return on Equity (ROE) Return on Assets (ROA) Revenue Per Share Free Cash Flow Per Share